ASHPOfficial

This episode will provide an overview of the parenteral multivitamin shortage and the impact this shortage has on neonatal and pediatric nutrition. Additionally, the use of alternative vitamin products and their availability will be discussed.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In the era of illicit fentanyl, the approach to buprenorphine induction has been adapted. Starting with low doses of buprenorphine can be applied to anyone taking a full agonist opioid, including cases of buprenorphine for chronic pain. We will discuss why, how, and what to consider as part of realistic implementation of low-dose buprenorphine induction therapy.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Does risk level “C” always mean “continue”? Join us as we delve into the current state of immune checkpoint inhibitor drug interaction reporting in common drug information resources and discuss how these interactions may be interpreted in daily clinical practice.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Prior to 2023, the “X-waiver” requirement prohibited pharmacists from prescribing buprenorphine as treatment for opioid use disorder (OUD). Now that the X-waiver has been eliminated, pharmacists now have more flexibility to engage in team-based OUD treatment via collaborative practice. This podcast will explore potential practice models relating to pharmacist-provided OUD treatment, review current laws and limitations on pharmacists engaging in controlled substance prescribing, and discuss advocacy initiatives to enhance pharmacists’ role as treatment providers. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Despite being developed in the late 1980s, Intrathecal pumps have been underutilized clinically for pain management for multiple reasons. With the opioid crisis and the significant increase in the proportion of the population with refractory pain, intrathecal pumps are gaining popularity.  Intrathecal pumps may be an appropriate option for improved pain control while minimizing side effects from systemic opioids.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Learn from pharmacy technicians who lead technician education and training in their institutions as they discuss advancing pharmacy technician career development.  

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode will provide an overview of excipients and dyes used in medications that often consumed by children. Topics will include an overview of specific excipients and dyes, allergies vs intolerance to substances, and an explanation of regulatory oversight.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast is a follow-up to the October webinar, A Day in the Life: Improving Collaboration to Minimize Exposure to Hazardous Drugs from Preparation to Administration and Beyond. Our experts will address audience questions that they were unable to answer during the webinar. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Ketamine use for the dual purpose of sedation and analgesia in the critical care setting has been increasing dramatically. Ketamine has a unique pharmacologic mechanism of action that has been shown to be effective for various types of pain, sedation and other indications such as alcohol withdrawal, which are commonly seen in an intensive care setting.  This podcast with review basic pharmacology and dosing of ketamine and provide guidance on appropriate patient selection for ketamine use in the ICU.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode, subject matter experts in health system organizations discuss the impact and changes in their organizations, due to accreditation updates in the specialty pharmacy space. This podcast is presented by members of the Accreditation and Compliance Section Advisory Group of the Section of Specialty Pharmacy Practitioners.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.